TRIM62 is a cytoplasmic RING finger E3 ubiquitin ligase that mediates innate immune responses and cell polarity. In antifungal immunity, TRIM62 catalyzes Lys-27-linked ubiquitination of CARD9 downstream of C-type lectin receptors, leading to CARD9 activation and downstream NF-κB and p38 mitogen-activated protein kinase signaling; this activity depends on the E2 enzyme UBE2D2 1. TRIM62 also regulates intestinal inflammation in inflammatory bowel disease contexts by controlling ubiquitination-dependent signaling 2, and small-molecule inhibitors targeting CARD9-TRIM62 interaction show promise in IBD therapeutics by mimicking a protective CARD9 variant 3. In cancer, TRIM62 acts as a tumor promoter: it is highly expressed in hepatocellular carcinoma and promotes proliferation, invasion, and chemoresistance through NF-κB pathway activation 4. Conversely, TRIM62 functions as a tumor suppressor in breast and lung cancer, where haploinsufficiency synergizes with oncogenic K-Ras to promote invasiveness 5. In pancreatic cancer, M2 macrophage-derived exosomal miR-193b-3p targets TRIM62, reducing its ubiquitination of c-Myc and promoting tumor progression 6. TRIM62 is also elevated in skeletal muscle of critically ill patients and may contribute to inflammation-induced atrophy through activator protein 1 signaling 7.